HepaRegeniX reports positive topline results of its Phase 1 Clinical Trial of HRX-0215, a First-In-Class MKK4 inhibitor
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
HRX-0215 proved to be safe and well tolerated in healthy volunteers.
He follows Dr. Graham Dixon who served as Chairman on the Board of HeparegeniX since 2017.